News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) and Astellas Pharma Inc. (YPH.BE) Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer



6/4/2012 10:29:10 AM

CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS (TivozAnib Use veRsUs Sutent in advanced renal cell carcinoma (RCC): Patient Preference), to establish additional data regarding the investigational drug tivozanib when used as first-line therapy in patients with advanced RCC. The TAURUS study will enroll patients at sites throughout the United States and Western Europe.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES